Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar, Xlucane
Posted on18 Jan 2016
TagsBiosimilar of Novartis' eye drug Lucentis launched in India, biosimilar version of Lucentis, biotech companies in the Middle East, Lucentis, Ranibizumab, Ranibizumab biosimilar, Xbrane, Xbrane Signs Deal With Helvetic BioPharma for its Lead Ranibizumab Biosimilar, Xlucane
Comments0
Xbrane Biopharma, a commercial phase biopharmaceutical company specialized in High Demand Complex Generics, announced that the company has signed a sales and... Read More
Intas launches RAZUMAB, the Biosimilar of Novartis’ eye drug Lucentis launched in India
Molecule Name: Ranibizumab Innovator Company: Novartis Biosimilar brand : Intas’s Ranibizumab Brand Name: RAZUMAB As the first company globally, Ahmedabad-based pharma major... Read More